Corporate Actions
Material events companies report to the SEC on Form 8-K: mergers, dividends, buybacks, splits, management changes, bankruptcies and more. Enter a ticker for one company's history, or browse the latest across the market.
Vir Biotechnology (VIR)
1 8-K filing| Filed | Action | What the filing says | SEC |
|---|---|---|---|
| Feb 23, 2026 |
Equity Issuance
Item 2.02Item 3.02Item 1.01Item 8.01Item 9.01
|
Results of Operations and Financial Condition. On February 23, 2026, Vir Bio issued a press release announcing its financial results for the quarter and full year ended December 31, 2025. A copy of the press release is…Results of Operations and Financial Condition. On February 23, 2026, Vir Bio issued a press release announcing its financial results for the quarter and full year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by Vir Bio under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 3.02 Unregistered Sales of Equity Securities. The information under I |
Filing |
Each 8-K is classified by its most significant item; hover an item number for its title. Classification and excerpts are read automatically and can be wrong; the filing on SEC.gov is the authority. For research, not investment advice.